China Shineway Pharmaceutical Group is an investment holding company. Via its subsidiaries, Co. is engaged in the research and development, manufacture and trading of Chinese pharmaceutical products. Co.'s six key products include Qing Kai Ling Injection for treatment of viral diseases including respiratory tract infection, Shen Mai Injection for treatment of coronary heart disease, Shu Xie Ning Injection for treatment of cardio-cerebrovascular disease, Wu Fu Xin Nao Qing Soft Capsule for treatment of coronary heart disease, Huo Xiang Zheng Qi Soft Capsule for prevention and treatment of heat stroke,and Pediatric Qing Fei Hua Tan Granule for children infected by respiratory related disease.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
A director at China Shineway Pharmaceutical Group Limited bought 657,000 shares at 6.902HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under ...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...
The general evaluation of SPIRIT AIRLINES INCO. (US), a company active in the Airlines industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date July 16, 2019, the closing price was USD 51.42 and its potential was estimated at USD 58.77.
CHARLES SCHWAB CORP. (US), a company active in the Investment Services industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 1 out of 4 possible stars; the general evaluation is slightly increased to Neutral but the title remains under pressure. As of the analysis date July 16, 2019, the closing price was USD 41.63 and its target price was estimated at USD 35.92.
The independent financial analyst theScreener just lowered the general evaluation of SAREPTA THERP.INCO. (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date July 16, 2019, the closing price was USD 153.25 and its target price was estimated at USD 95.95.
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.